Diabetes Pipeline Outlook: Evaluation of therapies anticipated

Los Angeles, USA, May 20, 2021 (GLOBE NEWSWIRE) – Diabetes pipeline outlook: analyzing therapies that are expected to have a significant impact in the next decade

The increasing prevalence of diabetes, particularly type 2 diabetes, has increased the demand for effective drug therapies to treat diabetes. There is another class of emerging drugs that can be administered orally or intravenously or subcutaneously.

DelveInsight’s ‘Insights into the Diabetes Pipeline‘ The report provides a detailed picture of the emerging therapies that are expected to hit the diabetes market along with that
a holistic view of the pipeline therapies being developed in both preclinical and clinical development stages and growth prospects across the diabetes area.

Some of the main highlights of the Diabetes pipeline Report:

• The Diabetes Pipeline Report offers a comprehensive analysis of Over 250 key players and Over 250 key therapies.
• Diabetes pipeline includes SCO-094 (Scohia Pharma), Tirzepatid (Eli Lilly and Company), LY-3502970 (Eli Lilly and Company), Volagidemab (REMD Biotherapeutics), Ladarixin (Dompe Farmaceutici), CT-388 (Carmot Therapeutics), GX G6 (Genexine), ORMD-0801 (Oramed) and several others.
• Of all emerging therapies MYL-1601DAn insulin-aspart biosimilar developed by US drug maker Mylan (now Viatris) and India-based biologics specialist Biocon has received marketing authorization from the European Commission (EC). It is the second insulin-aspart biosimilar to be approved in the EU. The central marketing authorization granted by the EC is valid in all member states of the European Union as well as in the countries of the European Economic Area (EEA) Iceland, Liechtenstein and Norway.
• Discovered using Lexicon’s Unique Approach to Genetic Science, p.otagliflozin is an oral dual inhibitor of two proteins responsible for regulating glucose, known as sodium-glucose co-transporters type 1 and 2 (SGLT1 and SGLT2).
• Novo Nordsik primarily contributes to the development of novel therapies for diabetes. FSI965, Insulin icodec, Insulin 147 and PCSK9i are the new therapies that are currently being investigated.
• Imeglimin is a novel drug for the treatment of diabetes that has completed Phase 3 development in Japan. A new drug application is currently being launched by Sumitomo Dainippon Pharma in fiscal 2021. Imeglimin is phase 3 capable in the US and Europe.
• Imeglimin is the only orally administered compound with a dual mechanism of action designed directly to both increase insulin secretion in response to glucose and decrease insulin resistance.
• LY3298176 (Dual GIP / GLP-1 Receptor Agonist) is a biological entity that acts as a coagonist for both the gastric inhibitory polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor and for treatment is being investigated by diabetes by Eli Lilly and Company.

Request a sample to learn more about the therapies designed to achieve the maximum patient pool @ Diabetes emerging therapies and prognoses

The Diabetes Pipeline Report includes business opportunities, threats, potential collaborations, strong competitors, growth strategies, and an in-depth analysis of failed and un discontinued drugs.

Diabetes: overview

Diabetes is a disease that occurs when blood sugar, also called blood sugar, becomes too high. Different types of diabetes are: Type 1 diabetes, an autoimmune disease, affects about 10 percent of all people with diabetes. Type 2 diabetes occurs when a person becomes insulin resistant. Pre-diabetes occurs when blood sugar is higher than normal but not high enough for a diagnosis of type 2 diabetes.
For more information about the disease and emerging drugs, see Diabetes pipeline analysis

Diabetes pipeline drugs

Request samples to learn more @ Diabetes pipeline analysis, key companies and futuristic trends

Diabetes Therapeutic Assessment

The Diabetes Pipeline Report provides comprehensive insights into active pipeline assets broken down by stage, molecule type, route of administration, product type, target and indications of various drugs.

By product type

On stage

• discovery
• Preclinical
• IND
• Phase I.
• Phase II
• Phase III
• Pre-registration

According to the type of molecule

• Small molecule
• Gene therapy
• Antihyperglycemics

On the way of administration

• Intravenously
• Intramuscular
• Orally
• Subcutaneous

By the mechanism of action

• Dipeptidyl peptidase 4 inhibitors
• Ornithine decarboxylase stimulants
• Glucagon-like peptide-1 receptor agonists
• Glucagon receptor antagonists
• Gastric inhibitory polypeptide receptor modulators
• Insulin-like growth factor binding protein inhibitors
• Gene transfer; Interleukin-10 replacement

According to goals

• Protease
• Multiple kinase

According to stage and route of administration
By phase and product type

Contact our Business Executive for Solutions for prioritizing and advising assets

Scope of the report

cover: Global
Key characters: Scohia Pharma, Eli Lilly and Company, Oramed, Genexine, Carmot Therapeutics, Dompe Farmaceutici, REMD Biotherapeutics, Precigen Inc., Yabao Pharmaceutical Group, Daewoong Pharmaceutical, AstraZeneca, BTB Pharma, Jiangsu Hengrui Medicine, CSPC ZhongQi Pharmaceutical Technology, Tiusion, Imcyse SA, Adocia, Innovent Biologics, Neuraly, Inc., Boehringer Ingelheim, Chia Tai Tianqing Pharmaceutical Group, OPKO Health, Novartis, Pfizer, vTv Therapeutics, Xeris Pharmaceuticals, PegBio Co., Akros Pharma, Lexicon Pharmaceuticals, Anelixis Therapeutics, Diasome Pharmaceuticals, Ionis Pharmaceuticals, Melior Pharmaceuticals, Chong Kun Dang, Arecor, Biocon and others
Important diabetes pipeline therapies: TRC150094, DBPR108, ORMD-0801, LY3298176, Cotadutide, BTB002, IMCY-0098, ADO09, IBI362, BTI320, NLY01, Insulin 338, SY-004, BI 456906, TQ-F3083, OPK-88003 HS-2000433, TTP273, PRAM9, PB-119, SCO-094, Tirzepatid, LY-3502970, ORMD-0801, GX G6, CT-388, Ladarixin, Volagidemab, AG019, SY-004, Enavogliflozin, Cotadutide, BTB002, INS068, DBPR108, TOL -3021, CLBS03, ISIS-GCGRRx, MLR-1023, JTT-662, CKD-393, AT278 and others.

Reach @ Diabetes Pipeline: Novel Therapies and New Technologies

Table of Contents

To learn more about what’s covered, visit @ Diabetes emerging therapies

Related reports

Dementia With Diabetes Market Forecast
DelveInsight’s’Dementia With Diabetes Market Insights, Epidemiology, and Market Forecast – 2030‘ Report.

Diabetes market
DelveInsight’s “Insights of the Diabetes Market, Epidemiology and Market Forecast – 2030” Report.

Gestational Diabetes Market
DelveInsight’s “Gestational Diabetes Market Insights, Epidemiology, and Market Forecast – 2030” Report.

Type 1 diabetes market
DelveInsight’s “Type 1 Diabetes Market Insights, Epidemiology, and Market Forecast – 2030” Report.

Type 2 Diabetes Market
DelveInsight’s “Type 2 Diabetes Market Insights, Epidemiology, and Market Forecast – 2030” Report.

Diabetes Pen Market Market
DelveInsight’s Insights of the Diabetes Pen Market, Competitive Landscape, and Market Forecast – 2026‘ Report.

Diabetic Eye Disease Market
DelveInsight’s “Diabetic Eye Diseases Market Insights, Epidemiology, and Forecast – 2030” Report.

Diabetic Ketoacidosis Market
DelveInsight’s “Diabetic Ketoacidosis (DKA) Market Insights, Epidemiology, and Forecast – 2030” Report.

related posts

Diabetic Peripheral Neuropathy Market Landscape
Prevalence of Diabetes and Its Complications
Chronic Pain Related to the Painful Diabetic Neuropathy Market Landscape

over DelveInsight

DelveInsight is a leading management consulting and research firm focused solely on the life sciences. It supports pharmaceutical companies by providing comprehensive end-to-end solutions to improve their performance. Get easy access to all market research reports for the healthcare and pharmaceutical industries through our subscription-based platform PharmDelve.

For more information, see Pharmaceutical, health and biotech news